The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2025

Filed:

Apr. 28, 2024
Applicant:

Immunitybio, Inc., Culver City, CA (US);

Inventors:

Patrick Soon-Shiong, Culver City, CA (US);

Elizabeth Gabitzsch, Culver City, CA (US);

Philip T. Liu, Culver City, CA (US);

Assignee:

ImmunityBio, Inc., Culver City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 40/15 (2024.12); A61K 40/24 (2024.12); A61K 40/42 (2024.12); C07K 14/47 (2005.12); C12N 5/0783 (2009.12); C12N 15/86 (2005.12);
U.S. Cl.
CPC ...
A61K 40/4201 (2024.12); A61K 40/15 (2024.12); A61K 40/24 (2024.12); C07K 14/4748 (2012.12); C12N 5/0646 (2012.12); C12N 15/86 (2012.12); C12N 2501/22 (2012.12); C12N 2501/2315 (2012.12); C12N 2501/26 (2012.12); C12N 2710/10343 (2012.12); C12N 2710/10362 (2012.12);
Abstract

An immunotherapeutic composition is contemplated that comprises subject-derived peripheral blood mononuclear cells (PBMC) and at least one recombinant adenovirus subtype 5 (Ad5) comprising a deletion in an E1 gene region, a deletion in an E2b gene region, and a nucleic acid sequence encoding a peptide antigen, wherein the PBMC are exposed ex-vivo to the at least one Ad5 vector. Advantageously, the same PBMC composition may also be used to prepare modified NK cells, and especially modified NK include CIML NK cells, CENK cells and mCENK cells.


Find Patent Forward Citations

Loading…